Fig. 1.
Design and pCR rate of neoadjuvant studies in HER2-positive breast cancer. Doce docetaxel, Tz trastuzumab, Pz pertuzumab, FEC 5-fluorouracil, epirubicin, and cyclophosphamide, Pacli paclitaxel, L lapatinib, IBC inflammatory breast cancer, LABC locally advanced breast cancer, pCR pathologic complete response